Department of Medical Sciences, University of Turin, Turin, Italy.
Rajalakshmi Hospital, Vidyaranyapura post.
Eur J Gastroenterol Hepatol. 2021 Feb 1;32(2):163-170. doi: 10.1097/MEG.0000000000001888.
The use of antisecretory drugs can provide symptomatic relief in 70-80% of patients suffering from gastro-oesophageal reflux disease (GORD), although this benefit is reduced by 20-30% in the case of nonerosive reflux disease (NERD). The current study evaluates the efficacy and safety of a patented oral formulation (liquid sachets containing hyaluronic acid, a mixture of amino acids including proline, hydroxyl-proline and glutamine, and rice extract dispersed in a bioadhesive polymer matrix) for relieving the symptoms of NERD.
A single-centre, randomized, double-blind, parallel group, placebo-controlled clinical study was performed. Patients who experienced at least three episodes of moderate-severity heartburn during the 7-day run-in period were included and treated with three liquid sachets per day for 14 days. The primary objective was to evaluate the proportion of patients with at least a three-point reduction in the total symptom score (TSS).
Overall, 20 patients were randomized to receive the investigational product and 20 to receive the placebo. At the end of treatment, a three-point reduction in the TSS was achieved by 95% of patients treated with the investigational product and by 20% of patients treated with placebo (P < 0.0001). No adverse events were reported.
The investigational product showed a statistically significant superiority to the placebo in relieving common symptoms in patients with NERD. Future studies will be aimed at clarifying the hypothesis that this symptomatic benefit is related to the strengthening of the oesophageal barrier against the damage induced by gastric contents.
抗分泌药物的使用可以为 70-80%的胃食管反流病(GORD)患者提供症状缓解,但在非糜烂性反流病(NERD)中,这种益处会降低 20-30%。本研究评估了一种专利口服制剂(含有透明质酸的液体小袋,一种包含脯氨酸、羟脯氨酸和谷氨酰胺的氨基酸混合物,以及分散在生物粘附聚合物基质中的大米提取物)缓解 NERD 症状的疗效和安全性。
进行了一项单中心、随机、双盲、平行组、安慰剂对照的临床研究。在 7 天的导入期内经历至少 3 次中度至重度烧心发作的患者被纳入并接受每天 3 个液体小袋治疗 14 天。主要目的是评估至少有 3 分总症状评分(TSS)降低的患者比例。
共有 20 名患者随机接受研究产品治疗,20 名患者接受安慰剂治疗。治疗结束时,接受研究产品治疗的患者中有 95%达到 TSS 降低 3 分,而接受安慰剂治疗的患者中只有 20%(P <0.0001)。未报告不良事件。
研究产品在缓解 NERD 患者常见症状方面明显优于安慰剂。未来的研究将旨在阐明这样一个假设,即这种症状缓解与食管屏障对胃内容物引起的损伤的增强有关。